Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838156 | 0.90 | SMO (0.43) | NR3C1NPBWR1MCHR1SMOCYP11B1 | |
| SCHEMBL838199 | 0.88 | NR3C1 (0.44) | NR3C1SMOCYP11B1CYP11B2PGR | |
| SCHEMBL838977 | 0.83 | SMO (0.43) | NR3C1SMOCYP11B1CYP11B2NPC1 | |
| SCHEMBL838558 | 0.80 | SMO (0.45) | NR3C1NPBWR1MCHR1SMOCYP11B1 | |
| SCHEMBL839293 | 0.77 | NR3C1 (0.48) | NR3C1NPBWR1CYP11B1CYP11B2PGR | |
| SCHEMBL838738 | 0.70 | HPGD (0.48) | NR3C1NPBWR1MCHR1SMOCYP11B1 | |
| SCHEMBL838181 | 0.68 | NR3C1 (0.47) | NR3C1SMOCYP11B1CYP11B2PGR | |
| SCHEMBL837429 | 0.67 | CYP11B1 (0.52) | NR3C1NPBWR1SMOCYP11B1CYP11B2 | |
| SCHEMBL27765911 | 0.67 | CYP11B1 (0.52) | NR3C1NPBWR1MCHR1SMOCYP11B1 | |
| SCHEMBL837357 | 0.67 | HPGD (0.48) | NR3C1SMOCYP11B1CYP11B2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885NPBWR1 129/4885MCHR1 201/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885NPBWR1 129/4885MCHR1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.